Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenacapavir + teropavimab + zinlirvimab versus cabotegravir + rilpivirine in virologically suppressed adults with HIV-1
NL-OMON61396Phase 3Not yet recruiting
- Sponsor
- Gilead Sciences
- Start
- Nov 2026
- Modality
- Small Molecules, Anti-infectious Disease mAbs → Neutralizing Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics, Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lenacapavir, Teropavimab, zinlirvimab, cabotegravir and rilpivirine in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Gilead Sciences. Primary endpoint: Proportion of participants with HIV-1 RNA at least 50 copies/mL at Week 52. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
lenacapavirTeropavimabzinlirvimabcabotegravirrilpivirine
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on NL-OMON61396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61396.